<DOC>
	<DOCNO>NCT02604160</DOCNO>
	<brief_summary>This study intend treat anemia chronic kidney disease determine safety study drug , LY3113593 . The study also evaluate much study drug get blood stream , long take body remove study drug , effect study drug body . The study consist three part . Participants may enroll one part . Participants receive four injection LY3113593 placebo vein . The study last 26 week include screen follow-up .</brief_summary>
	<brief_title>A Study LY3113593 Participants With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Receiving hemodialysis regularly ( least 3 time per week ) least 4 month Have hemoglobin value ( take prior dialysis , take dialysis day ) great equal 9.5 gram per deciliter ( g/dL ) less equal 11.0 g/dL screen Have receive erythropoiesis stimulate agent ( ESA ) injection least 4 week willing stop injection approximately 8 week Have another health condition may put participant risk study doctor feel would make participant unsuitable study Currently take part another study Have recently ( within 30 day ) complete study previously take part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>